Diaceutics PLC
LSE:DXRX
Intrinsic Value
Diaceutics Plc engages in the provision of data, data analytics and implementation services. [ Read More ]
The intrinsic value of one DXRX stock under the Base Case scenario is 92.68 GBX. Compared to the current market price of 104 GBX, Diaceutics PLC is Overvalued by 11%.
Valuation Backtest
Diaceutics PLC
Run backtest to discover the historical profit from buying and selling DXRX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Diaceutics PLC
Current Assets | 28m |
Cash & Short-Term Investments | 17.9m |
Receivables | 9.2m |
Other Current Assets | 874k |
Non-Current Assets | 18.2m |
PP&E | 2m |
Intangibles | 16.1m |
Other Non-Current Assets | 96k |
Current Liabilities | 3.5m |
Accounts Payable | 287k |
Accrued Liabilities | 1.7m |
Other Current Liabilities | 1.5m |
Non-Current Liabilities | 1.6m |
Long-Term Debt | 1.1m |
Other Non-Current Liabilities | 429k |
Earnings Waterfall
Diaceutics PLC
Revenue
|
21.9m
GBP
|
Cost of Revenue
|
-1.6m
GBP
|
Gross Profit
|
20.3m
GBP
|
Operating Expenses
|
-20.9m
GBP
|
Operating Income
|
-528k
GBP
|
Other Expenses
|
534k
GBP
|
Net Income
|
6k
GBP
|
Free Cash Flow Analysis
Diaceutics PLC
What is Free Cash Flow?
DXRX Profitability Score
Profitability Due Diligence
Diaceutics PLC's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
Diaceutics PLC's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
DXRX Solvency Score
Solvency Due Diligence
Diaceutics PLC's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Diaceutics PLC's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DXRX Price Targets Summary
Diaceutics PLC
According to Wall Street analysts, the average 1-year price target for DXRX is 169.93 GBX with a low forecast of 146.45 GBX and a high forecast of 210 GBX.
Shareholder Return
DXRX Price
Diaceutics PLC
Average Annual Return | -2.76% |
Standard Deviation of Annual Returns | 28.92% |
Max Drawdown | -60% |
Market Capitalization | 87.9m GBX |
Shares Outstanding | 84 679 296 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Diaceutics Plc engages in the provision of data, data analytics and implementation services. The company is headquartered in Belfast, Northern Ireland. The company went IPO on 2019-03-21. The principal activity of the Company is data analytics and implementation services. The firm is engaged in research and development activities in drug development science, testing data and software platform development. The firm's implementation services include test standardization, test quality assessment, laboratory tech support and others. The firm has established a range of products and outsourced advisory services, which help its pharma clients to optimize and deliver their marketing and implementation strategies for companion diagnostics. The firm provides the pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network. DXRX is the diagnostic commercialization platform for precision medicine, integrating multiple pipelines of diagnostic testing data from a global network of laboratories.
Contact
IPO
Employees
Officers
The intrinsic value of one DXRX stock under the Base Case scenario is 92.68 GBX.
Compared to the current market price of 104 GBX, Diaceutics PLC is Overvalued by 11%.